EGFR and lung cancer: In contrast, atypical EGFR variants, such as exon 20 insertions and less common point mutations (G719X, S768I, L861Q), often exhibit primary resistance to currently available TKIs, underscoring the biological heterogeneity of EGFR-driven lung cancer (2).